Patrick English is counsel in the Washington, D.C. office of Latham & Watkins and a member of the firm's Pro Bono Committee. He primarily advises on antitrust matters and regulatory and transactional matters for clients in the healthcare, medical device, and life sciences industries. Mr. English has assisted clients with HSR filings, represented clients in merger control proceedings before the Federal Trade Commission and Department of Justice, and counseled clients on internal investigations and compliance programs. He has also represented clients in criminal cartel proceedings and amnesty applications before the Department of Justice.
Mr. English has maintained a significant pro bono practice, the majority of which has been devoted to representing impoverished individuals with disabilities to gain access to disability benefits. He has also represented Holocaust survivors in their pursuit of reparations from the German government for work performed while in the ghetto. He previously served on the firm’s Recruiting Committee and is a former Co-Chair of the Global LGBTQ Affinity Group as well as the LGBTQ Affinity Group of the DC office. Outside of the office, Mr. English is former Co-Chair of both the Whitman Walker Health Walk to End HIV Legal Community Campaign, and the Steering Committee for Whitman Walker’s Going the Extra Mile event, of which he is still a member. He is also the organization’s pro bono liaison at Latham.
Mr. English is active within the leadership of the Antitrust Section of the American Bar Association, currently serving as a Chair on the Membership, Diversity & Inclusion (MD&I) Committee. He previously served as Vice Chair on the same Committee as well as Vice Chair on the Health Care and Pharmaceuticals Committee, and as the Health Care Committee’s Young Lawyer Representative.
Prior to joining Latham, Mr. English spent three years with the Federal Trade Commission in its Bureau of Competition as an Honors Paralegal and then Paralegal Specialist where he focused on mergers in the healthcare and life sciences sectors. He then earned his Juris Doctor from Northwestern University Law School and his Masters of Business Administration from the Kellogg School of Management, where he majored in biotechnology and concentrated on health industry management. He has also served as a Research Fellow for the American Antitrust Institute.
- Moderator and panel chair, “Medical Device vs. Pharmaceutical Markets – Does One Size (i.e., Analysis) Fit All?” ABA Health Care and Pharmaceuticals Committee Brown Bag, February 2018
- Moderator and panel chair, “Pharmaceutical Mergers and Innovation—Incentivizing V. Suppressing Development,” ABA Antitrust Spring Meeting, Washington D.C., March 2017
- Moderator and panel chair, “Divesting Placebos – Product Pipeline Merger Remedies,” ABA Health Care and Pharmaceuticals Committee Brown Bag, June 2016
- Co-Author, “DOJ Suit Against ValueAct Shines Spotlight on HSR Requirements for Shareholder Activists,” Latham & Watkins Client Alert, April 2016
- Panel chair, “Pay for Delay: Views From Both Sides of the Pond,” ABA Health Care and Pharmaceuticals Committee Brown Bag, June 2015
- Moderator and panel chair, “Dietary Supplement Health-Related Claims,” ABA Health Care and Pharmaceuticals Committee Brown Bag, February 2014
Mr. English’s experience includes the representation of:
- Amneal Pharmaceuticals in its US$1.4 billion business combination with Impax Laboratories
- Integra LifeSciences Holdings Corporation in its US$1.05 billion acquisition of Johnson & Johnson’s Codman Neurosurgery business
- Cannery Casino Resorts in the sale of two Las Vegas properties to Boyd Gaming Corporation
- Gavis Pharmaceuticals in its US$880 million sale to Lupin
- Entercom Communications Corp. in its US$105 million acquisition of Lincoln Financial Media
- Veyance Technologies in its US$1.9 billion acquisition by Continental AG
- Arthrocare in its US$1.7 billion merger with Smith & Nephew
- Leap Wireless in its US$1.2 billion sale to AT&T
- Vitamin Shoppe in its US$50 million acquisition of Super Supplements
- Medicis in its US$2.6 billion sale to Valeant